Immunotherapy research progress of intrahepatic cholangiocarcinoma
10.3760/cma.j.cn115396-20220317-00087
- VernacularTitle:肝内胆管癌的免疫治疗研究进展
- Author:
Guixiang WANG
1
;
Yaoming ZHANG
Author Information
1. 广东医科大学，湛江 524000
- Keywords:
Bile duct neoplasms;
Bile ducts, intrahepatic;
Therapeutic uses;
Intrahepatic cholangiocarcinoma;
Immunotherapy;
Tumor microenvironment
- From:
International Journal of Surgery
2022;49(8):567-571
- CountryChina
- Language:Chinese
-
Abstract:
Intrahepatic cholangiocarcinoma is a primary hepatic malignant tumor with high malignancy and poor prognosis. In addition to surgical resection, there are no clear studies showing that there are other effective treatments. In recent years, with the deepening of the research on the immune mechanism of various malignant tumors, immunotherapy has been gradually attached importance to various anti-solid tumor treatments, and has also become an important direction in the treatment of intrahepatic cholangiocarcinoma. The important role of tumor microenvironment in the immunotherapy of malignant tumors is gradually recognized. In this paper, the characteristics of immune microenvironment in intrahepatic cholangiocarcinoma has been summarized, and the application of immunotherapy in intrahepatic cholangiocarcinoma has been reviewed, with emphasis on the development of immune checkpoint inhibitors, cancer vaccines and adoptive cellular immunotherapy.
